Viracta Therapeutics Inc (NASDAQ: VIRX) on Friday, soared 5.79% from the previous trading day, before settling in for the closing price of $0.15. Within the past 52 weeks, VIRX’s price has moved between $0.13 and $1.31.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 134.94%. The company achieved an average annual earnings per share of 31.57%. With a float of $27.94 million, this company’s outstanding shares have now reached $39.09 million.
Let’s determine the extent of company efficiency that accounts for 40 employees. In terms of profitability, gross margin is 55.42%, operating margin of -6397.02%, and the pretax margin is -5865.72%.
Viracta Therapeutics Inc (VIRX) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Viracta Therapeutics Inc is 29.69%, while institutional ownership is 13.00%. The most recent insider transaction that took place on Feb 27 ’24, was worth 2,493. In this transaction CFO and COO of this company sold 3,405 shares at a rate of $0.73, taking the stock ownership to the 102,306 shares. Before that another transaction happened on Nov 30 ’23, when Company’s President and CEO bought 52,094 for $0.49, making the entire transaction worth $25,734. This insider now owns 52,094 shares in total.
Viracta Therapeutics Inc (VIRX) Recent Fiscal highlights
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.35 earnings per share (EPS) for the period falling under the consensus outlook (set at -0.31) by -0.04. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 31.57% per share during the next fiscal year.
Viracta Therapeutics Inc (NASDAQ: VIRX) Trading Performance Indicators
Viracta Therapeutics Inc (VIRX) is currently performing well based on its current performance indicators. A quick ratio of 0.76 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.10, a number that is poised to hit -0.19 in the next quarter and is forecasted to reach -0.51 in one year’s time.
Technical Analysis of Viracta Therapeutics Inc (VIRX)
Looking closely at Viracta Therapeutics Inc (NASDAQ: VIRX), its last 5-days average volume was 0.57 million, which is a jump from its year-to-date volume of 0.49 million. As of the previous 9 days, the stock’s Stochastic %D was 44.14%. Additionally, its Average True Range was 0.02.
During the past 100 days, Viracta Therapeutics Inc’s (VIRX) raw stochastic average was set at 6.51%, which indicates a significant decrease from 39.95% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 59.21% in the past 14 days, which was lower than the 78.06% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.2096, while its 200-day Moving Average is $0.5527. However, in the short run, Viracta Therapeutics Inc’s stock first resistance to watch stands at $0.1670. Second resistance stands at $0.1733. The third major resistance level sits at $0.1816. If the price goes on to break the first support level at $0.1524, it is likely to go to the next support level at $0.1441. Now, if the price goes above the second support level, the third support stands at $0.1378.
Viracta Therapeutics Inc (NASDAQ: VIRX) Key Stats
Market capitalization of the company is 6.76 million based on 39,744K outstanding shares. Right now, sales total 0 K and income totals -51,060 K. The company made 0 K in profit during its latest quarter, and -10,550 K in sales during its previous quarter.
